| Not Yet Recruiting | Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or NCT06726330 | Centre Oscar Lambret | N/A |
| Not Yet Recruiting | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence NCT07495124 | University of Washington | Phase 2 |
| Recruiting | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) NCT07480954 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Not Yet Recruiting | Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance NCT07269574 | Tongji Hospital | — |
| Recruiting | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adju NCT06915025 | Imunon | Phase 3 |
| Not Yet Recruiting | Surgery for Relapsed Ovarian Cancer in Precision NCT06602063 | Shanghai Gynecologic Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer NCT07023484 | The University of Hong Kong | Phase 2 |
| Completed | Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovar NCT06870539 | Mayo Clinic | — |
| Recruiting | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Plati NCT05460000 | North Eastern German Society of Gynaecological Oncology | Phase 2 |
| Active Not Recruiting | Diet, Hepcidin, and Chemotherapy RDI NCT06483997 | George Washington University | — |
| Recruiting | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in NCT06469281 | Regeneron Pharmaceuticals | Phase 1 |
| Recruiting | Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients Wit NCT06492070 | Emory University | Phase 2 |
| Recruiting | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression NCT06420973 | Peking University Cancer Hospital & Institute | Phase 2 |
| Active Not Recruiting | A Study of Sovilnesib in Subjects With Ovarian Cancer NCT06084416 | Volastra Therapeutics, Inc. | Phase 1 |
| Unknown | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARP NCT06161272 | Guangxi Medical University | Phase 2 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors NCT05858736 | OncoC4, Inc. | Phase 1 |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Completed | A Study of CDX-585 in Patients With Advanced Malignancies NCT05788484 | Celldex Therapeutics | Phase 1 |
| Active Not Recruiting | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers NCT05527184 | AbbVie | Phase 1 |
| Active Not Recruiting | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer NCT05446298 | OncoC4, Inc. | Phase 2 |
| Terminated | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary NCT05538624 | Avenge Bio, Inc | Phase 1 / Phase 2 |
| Recruiting | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 | Genmab | Phase 1 / Phase 2 |
| Unknown | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer NCT05043402 | OncXerna Theraputics, Inc. | Phase 3 |
| Withdrawn | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care NCT04368130 | Dana-Farber Cancer Institute | N/A |
| Completed | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers NCT05483933 | Shattuck Labs, Inc. | Phase 1 |
| Terminated | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer NCT05261490 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer NCT05200260 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Recruiting | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) NCT05429970 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Terminated | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in NCT05200364 | Sutro Biopharma, Inc. | Phase 1 |
| Active Not Recruiting | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian NCT04575961 | North Eastern German Society of Gynaecological Oncology | Phase 2 |
| Recruiting | Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer NCT05236686 | Shanghai Gynecologic Oncology Group | N/A |
| Completed | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer NCT05198804 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies NCT05199272 | 23andMe, Inc. | Phase 1 / Phase 2 |
| Unknown | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma NCT05537844 | Liz-Anne Lewsley | — |
| Terminated | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy NCT04814875 | THERAPIM PTY LTD | Phase 1 / Phase 2 |
| Withdrawn | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, NCT03607955 | Washington University School of Medicine | Phase 1 |
| Unknown | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary P NCT04375956 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 2 |
| Recruiting | A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care NCT04834544 | Peking University Third Hospital | Phase 2 |
| Not Yet Recruiting | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) NCT04515602 | Shanghai Gynecologic Oncology Group | Phase 3 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Completed | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies NCT04440943 | Celldex Therapeutics | Phase 1 |
| Completed | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer NCT04406623 | Shattuck Labs, Inc. | Phase 1 |
| Unknown | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer F NCT04229615 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy NCT04201561 | Seoul National University Hospital | Phase 3 |
| Active Not Recruiting | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy NCT04204811 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) NCT03891576 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Completed | Phase I Trial HIPEC With Nal-irinotecan NCT04088786 | Stony Brook University | Phase 1 |
| Completed | The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer NCT03921658 | University of Minnesota | — |
| Recruiting | Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) NCT03983226 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Unknown | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery NCT03373058 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 3 |
| Terminated | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) NCT03824704 | pharmaand GmbH | Phase 2 |
| Completed | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives NCT04257045 | M.D. Anderson Cancer Center | — |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Completed | Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian T NCT06274541 | Cancer Trials Ireland | — |
| Unknown | HIPEC After Initial CRS in Patients Who Have Received NACT NCT03540017 | Northwell Health | Phase 1 |
| Completed | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Canc NCT03748186 | Sutro Biopharma, Inc. | Phase 1 |
| Recruiting | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer NCT03783949 | Universitaire Ziekenhuizen KU Leuven | Phase 2 |
| Terminated | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Perito NCT03585764 | University of Pennsylvania | Phase 1 |
| Completed | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (o NCT03648489 | Imperial College London | Phase 2 |
| Terminated | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mes NCT03608618 | MaxCyte, Inc. | Phase 1 |
| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Unknown | BEACON - ABC in Recurrent Platinum Resistant HGSOC NCT03363867 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Active Not Recruiting | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma NCT06972693 | European Institute of Oncology | Phase 4 |
| Completed | Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers NCT03604653 | Holy Name Medical Center, Inc. | — |
| Active Not Recruiting | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas NCT03355976 | Brown University | Phase 2 |
| Unknown | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Can NCT03283943 | British Columbia Cancer Agency | Phase 1 |
| Unknown | Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian NCT03180177 | Shu-Zhong Cui | Phase 3 |
| Active Not Recruiting | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Periton NCT03029403 | University Health Network, Toronto | Phase 2 |
| Unknown | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epitheli NCT02033616 | Aivita Biomedical, Inc. | Phase 2 |
| Terminated | Anti-PD-L1 and SAbR for Ovarian Cancer NCT03312114 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian C NCT03297489 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | The Treatment Preferences of Women Diagnosed With Ovarian Cancer NCT03367260 | Duke University | — |
| Unknown | EDMONd - Elemental Diet in Bowel Obstruction NCT03150992 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Active Not Recruiting | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) NCT02859038 | Shanghai Gynecologic Oncology Group | Phase 3 |
| Unknown | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life NCT03000192 | University Hospital Southampton NHS Foundation Trust | — |
| Terminated | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer NCT02661815 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers NCT02725489 | Mary Crowley Medical Research Center | Phase 2 |
| Completed | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer NCT02788708 | Floor Backes | Phase 1 |
| Active Not Recruiting | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer NCT02345265 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor ( NCT02631876 | ImmunoGen, Inc. | Phase 3 |
| Terminated | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fa NCT02485990 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Unknown | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or NCT02584478 | Advenchen Laboratories, LLC | Phase 3 |
| Unknown | Total/Subtotal Colectomy in Ovarian Cancer NCT02595021 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malig NCT02578888 | Albert Einstein College of Medicine | N/A |
| Completed | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Und NCT02315469 | NRG Oncology | — |
| Completed | A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent NCT02344095 | Seoul National University Hospital | Phase 1 |
| Completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With O NCT02166905 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Periton NCT02118285 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Unknown | Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage NCT03150121 | Sheba Medical Center | N/A |
| Active Not Recruiting | HOT: HIPEC in Ovarian Cancer as Initial Treatment NCT02124421 | Mercy Medical Center | Phase 2 |
| Completed | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube C NCT01974765 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Tivozanib As Maintenance Therapy In GYN NCT01972516 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian NCT01952249 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? NCT01611766 | Shanghai Gynecologic Oncology Group | Phase 3 |
| Completed | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma NCT01519869 | Rachel Miller | Phase 2 |
| Terminated | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer NCT01535157 | South Plains Oncology Consortium | Phase 1 / Phase 2 |
| Unknown | Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients Wit NCT02328716 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Phase 3 |
| Completed | Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer NCT01442051 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma NCT01381861 | Tracon Pharmaceuticals Inc. | Phase 2 |
| Completed | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresect NCT02217956 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 |
| Completed | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Perit NCT01295489 | Gynecologic Oncology Group | — |
| Withdrawn | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-01 NCT01445275 | Gynecologic Oncology Group | — |
| Completed | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, o NCT01118052 | Gynecologic Oncology Group | Phase 2 |
| Terminated | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer NCT01202890 | New Mexico Cancer Research Alliance | Phase 1 |
| Completed | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer NCT01031381 | University of Pittsburgh | Phase 2 |
| Unknown | Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer NCT01180504 | University Hospital Heidelberg | Phase 2 |
| Completed | Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients NCT01308944 | Washington University School of Medicine | Phase 1 |
| Completed | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer NCT01139957 | Gynecologic Oncology Group | — |
| Withdrawn | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer NCT01138137 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial NCT01506856 | Gynecologic Oncology Trial & Investigation Consortium | Phase 2 / Phase 3 |
| Completed | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Lin NCT01709487 | Jules Bordet Institute | Phase 1 / Phase 2 |
| Completed | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ov NCT01097746 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer NCT01091259 | NYU Langone Health | Phase 2 |
| Unknown | Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary NCT00958698 | Gynecologic Oncology Group | N/A |
| Completed | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Prim NCT00939809 | Gynecologic Oncology Group | Phase 2 |
| Completed | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer NCT01669226 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Completed | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithe NCT00814086 | Gynecologic Oncology Group | Phase 1 |
| Completed | Study of Ramucirumab in Ovarian Cancer NCT00721162 | Eli Lilly and Company | Phase 2 |
| Completed | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma NCT00868192 | Washington University School of Medicine | Phase 2 |
| Completed | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer NCT00551070 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial NCT00551265 | Gynecologic Oncology Group | N/A |
| Completed | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors NCT00561795 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer NCT00511992 | University of Oklahoma | Phase 2 |
| Completed | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovari NCT00499252 | Gynecologic Oncology Group | Phase 2 |
| Completed | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer NCT00407563 | Accelerated Community Oncology Research Network | Phase 2 |
| Completed | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopi NCT00301756 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, NCT00352300 | Gynecologic Oncology Group | Phase 1 |
| Recruiting | Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors NCT00488878 | M.D. Anderson Cancer Center | — |
| Terminated | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer NCT00322881 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinom NCT00582205 | University of Oklahoma | Phase 2 |
| Completed | Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients NCT00478452 | University of Pennsylvania | Phase 1 |
| Completed | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer NCT00093626 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels NCT00083928 | Ångstrom Pharmaceuticals | Phase 2 |
| Completed | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Pe NCT00072566 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ova NCT00066456 | Gynecologic Oncology Group | Phase 1 |
| Completed | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopia NCT00060359 | Gynecologic Oncology Group | Phase 1 |
| Completed | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal NCT00054119 | Gynecologic Oncology Group | Phase 2 |
| Completed | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Canc NCT00045682 | Gynecologic Oncology Group | Phase 2 |
| Completed | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer NCT00214058 | University of Wisconsin, Madison | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary NCT00011986 | Gynecologic Oncology Group | Phase 3 |
| Terminated | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian NCT00004221 | Gynecologic Oncology Group | Phase 2 |